The company completed the purchase of a nutritional factory near Auckland, New Zealand at Pokeno during the year.
Excluding the Pokeno costs, underlying net profit after tax was $235.8 million, up seven per cent.
a2 MIlk has a processing facility at Smeaton Grange, NSW, and draws on milk processed by selected third parties including Kyvalley Dairies.
Company chair Pip Greenwood said the company entered the year with strong momentum and delivered a positive first half result in February, with the company trading ahead of plan and achieving growth across all product categories and markets.
“However, as we entered the fourth quarter, we experienced supply chain challenges, largely outside the company’s control, that significantly affected product availability in China.
The company was impacted by shortfalls of China label IMF product that materially impacted in-market product availability during the fourth quarter of 2026 and necessitated a large proportion of existing users to switch to alternative brands, with the flow-on effects expected to impact this year’s sales.
“During this period, we also managed a limited product recall in the US,” Ms Greenwood said.
“While this was disappointing after such a strong start to the year, these events do not change our long-term strategy, the confidence we have in the strength of our brand, or the opportunities ahead.”
The market in the US was affected by a voluntary recall in May of infant formula sold only in the US.
No confirmed incidents of illness were reported, according to the US Food and Drug administration.
In his outlook for the company, CEO and managing director David Bortolussi said the company expected future revenue growth of mid single digit percent, with the first half of 2027 revenue slightly down on the same period last year.
The a2 Milk Company was founded in 2000 in New Zealand by scientist Dr Corran (Corrie) McLachlan and his business partner Howard Paterson, who recognised that not all milk is the same.
Originally all cows produced milk containing only A2 beta-casein protein, but over many years the A1 protein developed in some cows’ milk.
Results of several published peer-reviewed human clinical trials have shown that A1 protein can cause digestive issues for some people.
A2 milk is sourced from selected cows that naturally produce milk containing only A2-type beta-casein protein and no A1.
The company’s current product portfolio includes fresh milk, ultra-heat treated milk, extended shelf life milk, infant milk formula, plain milk powders (including instant whole and skim milk powder), fortified milk powders for children and seniors, paediatric supplements and other dairy nutritional products, providing high quality nutrition for infants, children, adults, pregnant women and seniors.
The company primarily operates in the China, Australia, New Zealand, Vietnam, South Korea and North America markets.